AstraZeneca issues disappointing guidance

MORNINGSTAR VIEW: Fourth-quarter results are in line with our expectations but 2010 EPS guidance is disappointing

Damien Conover, CFA 28 January, 2010 | 6:26PM
Facebook Twitter LinkedIn

AstraZeneca reported fourth-quarter results in line with our expectations. However the company issued disappointing 2010 earnings-per-share guidance of $5.75 to $6.15, which is slightly below our projections. Based on the company's outlook, we will likely refine our estimates, which may lead to a slightly reduced fair value estimate. Read our full analysis for further details on estimates and fair value.

In the fourth quarter, total sales increased 4% year-over-year, excluding the impact of foreign exchange rates. Sales of H1N1 vaccines and reduced generic competition for cardiovascular drug Toprol added support to the top line. We expect both of these trends to dissipate in 2010 as Watson has recently entered the generic Toprol market and other generic manufactures will likely come on line later in the year. Further, based on declining concern about H1N1, we expect sales for the vaccine in 2010 to decline.

The company's core product line generated sales in line with our expectations. Strong sales growth from cardiovascular drug Crestor and respiratory drug Symbicort offset weakness from a patent loss on oncology drug Casodex. We expect these trends to continue through 2010.

On the bottom line, cost improvements led to an earnings-per-share increase of 7% versus the prior year period. However, much of the cost containment was due to lower intangible asset impairment charges, which appear to resemble financial management rather than actual fundamental changes in operating structure. Further, the company redeployed some of the savings toward increasing marketing expenses. We believe Astra should more aggressively follow its peer group in cutting costs as the company needs to become more efficient in light of the major patent losses facing the company during the next ten years.

Damien Conover, CFA is a Morningstar equity analyst.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC11,968.00 GBX5.43Rating

About Author

Damien Conover, CFA  is an equity analyst and associate director at Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures